Latest News and Press Releases

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...

Pharming Group announces 2026 financial guidance and highlights rare disease pipeline (PIDs and PMD) at Investor Day today Feb. 3 at 10:00am EST.

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 ...

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease...

Austin, TX, USA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Spatial Biology Market Size, Trends and Insights By Molecular Technology...

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial...

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Pharming announced preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026 at 10:00 EST.

Alumis Announces Proposed Public Offering of Common Stock

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program